Excitement Over MS Stem Cell Transplant 'Game Changer' Data
An international trial has demonstrated that HSCT was more effective than standard drugs for people with highly active relapsing-remitting multiple sclerosis. Also a one-off transplant compared to lifelong therapy has considerable cost-saving implications.
You may also be interested in...
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
The Mallorca-based biotech is building a strong data package for SNF472 which the company believes will be an effective treatment for a number of calcification disorders in dialysis patients.
The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.